Idogen AB (publ) announced that the organization has been strengthened with several leading key roles before the company's most advanced drug candidate enters the clinical development phase. The management team is thus expanded with competence and experience in both early drug development and clinical trials. The company is now strengthening the organization with three new employees.

Idogen has appointed Hanjing Xie as Chief Medical Officer, CMO, with responsibility for the clinical development of the company's cell therapy treatment IDO 8. Hanjing Xie most recently came from Oncopeptides, where she was Senior Medical Study Director. She is a doctor and specialist in hematology, oncology and internal medicine and has over 20 years of clinical experience, mostly from Karolinska University Hospital, as well as extensive experience from clinical trials. She also has experience of clinical use of cell therapy treatments and is an associate professor at Karolinska Institutet.

Hanjing Xie took office in January 2022. Rory Graham has been appointed Chief Regulatory Officer, CRO, and will take up the post immediately. Rory Graham will continue the regulatory work on IDO 8 and additional applications to ensure the start of the planned Phase 1/2a study.

He will also work to optimize the regulatory strategy in Europe and the United States to enable an efficient development process of IDO T, the company's drug candidate in the transplant field. Rory Graham has extensive experience of regulatory processes in both Europe and the United States, as well as extensive knowledge of cell therapies and biological drugs.